{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:12:43Z","timestamp":1790179963293,"version":"4.1.0"},"reference-count":40,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T00:00:00Z","timestamp":1490227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Several cannabinoids afforded neuroprotection in experimental models of Huntington\u2019s disease (HD). We investigated whether a 1:1 combination of botanical extracts enriched in either \u22069-tetrahydrocannabinol (\u22069-THC) or cannabidiol (CBD), which are the main constituents of the cannabis-based medicine Sativex\u00ae, is beneficial in R6\/2 mice (a transgenic model of HD), as it was previously shown to have positive effects in neurotoxin-based models of HD. We recorded the progression of neurological deficits and the extent of striatal deterioration, using behavioral, in vivo imaging, and biochemical methods in R6\/2 mice and their corresponding wild-type mice. The mice were daily treated, starting at 4 weeks after birth, with a Sativex-like combination of phytocannabinoids (equivalent to 3 mg\/kg weight of pure CBD + \u22069-THC) or vehicle. R6\/2 mice exhibited the characteristic deterioration in rotarod performance that initiated at 6 weeks and progressed up to 10 weeks, and elevated clasping behavior reflecting dystonia. Treatment with the Sativex-like combination of phytocannabinoids did not recover rotarod performance, but markedly attenuated clasping behavior. The in vivo positron emission tomography (PET) analysis of R6\/2 animals at 10 weeks revealed a reduced metabolic activity in the basal ganglia, which was partially attenuated by treatment with the Sativex-like combination of phytocannabinoids. Proton nuclear magnetic resonance spectroscopy (H+-MRS) analysis of the ex vivo striatum of R6\/2 mice at 12 weeks revealed changes in various prognostic markers reflecting events typically found in HD patients and animal models, such as energy failure, mitochondrial dysfunction, and excitotoxicity. Some of these changes (taurine\/creatine, taurine\/N-acetylaspartate, and N-acetylaspartate\/choline ratios) were completely reversed by treatment with the Sativex-like combination of phytocannabinoids. A Sativex-like combination of phytocannabinoids administered to R6\/2 mice at the onset of motor symptoms produced certain benefits on the progression of striatal deterioration in these mice, which supports the interest of this cannabinoid-based medicine for the treatment of disease progression in HD patients.<\/jats:p>","DOI":"10.3390\/ijms18040684","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T06:40:37Z","timestamp":1490251237000},"page":"684","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6\/2 Mice, an Experimental Model of Huntington\u2019s Disease"],"prefix":"10.3390","volume":"18","author":[{"given":"Sara","family":"Valdeolivas","sequence":"first","affiliation":[{"name":"Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular, Instituto Universitario de Investigaci\u00f3n en Neuroqu\u00edmica, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain"},{"name":"Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onintza","family":"Sagredo","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular, Instituto Universitario de Investigaci\u00f3n en Neuroqu\u00edmica, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain"},{"name":"Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Delgado","sequence":"additional","affiliation":[{"name":"Unidad de Cartograf\u00eda Cerebral, Instituto Pluridisciplinar, Universidad Complutense, 28040 Madrid, Spain"},{"name":"Departamento de Farmacolog\u00eda, Facultad de Farmacia, Universidad Complutense, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Pozo","sequence":"additional","affiliation":[{"name":"Unidad de Cartograf\u00eda Cerebral, Instituto Pluridisciplinar, Universidad Complutense, 28040 Madrid, Spain"},{"name":"Departamento de Fisiolog\u00eda, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4490-0604","authenticated-orcid":false,"given":"Javier","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[{"name":"Departamento de Bioqu\u00edmica y Biolog\u00eda Molecular, Instituto Universitario de Investigaci\u00f3n en Neuroqu\u00edmica, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Neurodegenerativas (CIBERNED), 28040 Madrid, Spain"},{"name":"Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-4419-6448-9_5","article-title":"Huntington\u2019s disease","volume":"685","author":"Roze","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1093\/hmg\/ddq148","article-title":"Huntington\u2019s disease: Progress toward effective disease-modifying treatments and a cure","volume":"19","author":"Johnson","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","article-title":"A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease","volume":"263","author":"Sagredo","year":"2016","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.2174\/138161208785740108","article-title":"The endocannabinoid system in Huntington\u2019s disease","volume":"14","author":"Pazos","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1517\/14728221003709792","article-title":"The endocannabinoid system as a target for the treatment of neuronal damage","volume":"14","author":"Sagredo","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1097\/00001756-200410250-00015","article-title":"Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo","volume":"15","author":"Bizat","year":"2004","journal-title":"Neuroreport"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1460-9568.2007.05717.x","article-title":"Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors","volume":"26","author":"Sagredo","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s13311-014-0304-z","article-title":"Neuroprotective properties of cannabigerol in Huntington\u2019s disease: Studies in R6\/2 mice and 3-nitropropionate-lesioned mice","volume":"12","author":"Valdeolivas","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/brain\/awq278","article-title":"Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington\u2019s disease","volume":"134","author":"Chiarlone","year":"2011","journal-title":"Brain"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington\u2019s disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.neuropharm.2006.06.013","article-title":"The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum","volume":"51","author":"Pintor","year":"2006","journal-title":"Neuropharmacology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuroscience.2010.06.056","article-title":"Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington\u2019s disease transgenic mice","volume":"170","author":"Dowie","year":"2010","journal-title":"Neuroscience"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/ern.11.47","article-title":"THC and CBD oromucosal spray (Sativex\u00ae) in the management of spasticity associated with multiple sclerosis","volume":"11","author":"Vila","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11539000-000000000-00000","article-title":"Role of cannabinoids in multiple sclerosis","volume":"25","author":"Zajicek","year":"2011","journal-title":"CNS Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","article-title":"Emerging strategies for exploiting cannabinoid receptor agonists as medicines","volume":"156","author":"Pertwee","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1002\/jnr.22682","article-title":"Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington\u2019s disease","volume":"89","author":"Sagredo","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00001756-200305060-00007","article-title":"Effects of cannabinoids in the rat model of Huntington\u2019s disease generated by an intrastriatal injection of malonate","volume":"14","author":"Bizat","year":"2003","journal-title":"Neuroreport"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1021\/cn200114w","article-title":"Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease: Role of CB1 and CB2 receptors","volume":"3","author":"Valdeolivas","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/jcbfm.2014.257","article-title":"In vivo and ex vivo magnetic resonance spectroscopy of the infarct and the subventricular zone in experimental stroke","volume":"35","author":"Davila","year":"2015","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.03.027","article-title":"Mechanisms of cannabidiol neuroprotection in hypoxic-ischemic newborn pigs: Role of 5HT1A and CB2 receptors","volume":"71","author":"Pazos","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3389\/fnins.2016.00323","article-title":"Effects of cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-ischemia","volume":"10","author":"Lafuente","year":"2016","journal-title":"Front. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1021\/pr050244o","article-title":"Metabolic characterization of the R6\/2 transgenic mouse model of Huntington\u2019s disease by high-resolution MAS 1H NMR spectroscopy","volume":"5","author":"Tsang","year":"2006","journal-title":"J. Proteome Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.bbadis.2011.08.001","article-title":"1H NMR based metabolomics of CSF and blood serum: A metabolic profile for a transgenic rat model of Huntington disease","volume":"1812","author":"Verwaest","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Heikkinen, T., Lehtim\u00e4ki, K., Vartiainen, N., Puoliv\u00e4li, J., Hendricks, S.J., Glaser, J.R., Bradaia, A., Wadel, K., Touller, C., and Kontkanen, O. (2012). Characterization of neurophysiological and behavioral changes, MRI brain volumetry and 1H MRS in zQ175 knock-in mouse model of Huntington\u2019s disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050717"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JHD-140116","article-title":"Novel BAC mouse model of Huntington\u2019s disease with 225 CAG repeats exhibits an early widespread and stable degenerative phenotype","volume":"4","author":"Wegrzynowicz","year":"2015","journal-title":"J. Huntingt. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"15658","DOI":"10.1523\/JNEUROSCI.1830-14.2014","article-title":"Differential effects of delayed aging on phenotype and striatal pathology in a murine model of Huntington disease","volume":"34","author":"Sadagurski","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1021\/acs.jproteome.6b00049","article-title":"Novel metabolite biomarkers of Huntington\u2019s disease as detected by High-Resolution Mass Spectrometry","volume":"15","author":"Graham","year":"2016","journal-title":"J. Proteome Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neures.2006.01.002","article-title":"Contribution of reduced and oxidized glutathione to signals detected by magnetic resonance spectroscopy as indicators of local brain redox state","volume":"55","author":"Satoh","year":"2006","journal-title":"Neurosci. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Mov. Disord."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1176\/jnp.2006.18.4.553","article-title":"Nabilone could treat chorea and irritability in Huntington\u2019s disease","volume":"18","author":"Curtis","year":"2006","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/1531-8257(199911)14:6<1038::AID-MDS1024>3.0.CO;2-7","article-title":"Nabilone increases choreatic movements in Huntington\u2019s disease","volume":"14","author":"Schneider","year":"1999","journal-title":"Mov. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","article-title":"Controlled clinical trial of cannabidiol in Huntington\u2019s disease","volume":"40","author":"Consroe","year":"1991","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/ejn.12202","article-title":"Decreased expression of GLT-1 in the R6\/2 model of Huntington\u2019s disease does not worsen disease progression","volume":"38","author":"Petr","year":"2013","journal-title":"Eur. J. Neurosci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/ern.12.12","article-title":"Evaluation of the safety and tolerability profile of Sativex: Is it reassuring enough?","volume":"12","author":"Wade","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1523\/JNEUROSCI.20-12-04389.2000","article-title":"Neuroprotective effects of creatine in a transgenic mouse model of Huntington\u2019s disease","volume":"20","author":"Ferrante","year":"2000","journal-title":"J. Neurosci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/nbdi.2001.0406","article-title":"Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington\u2019s disease","volume":"8","author":"Andreassen","year":"2001","journal-title":"Neurobiol. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/01.WNL.0000070186.97463.A7","article-title":"Creatine therapy for Huntington\u2019s disease: Clinical and MRS findings in a 1-year pilot study","volume":"61","author":"Tabrizi","year":"2003","journal-title":"Neurology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neuroimage.2014.04.004","article-title":"Towards a reproducible protocol for repetitive and semi-quantitative rat brain imaging with 18F-FDG: Exemplified in a memantine pharmacological challenge","volume":"96","author":"Deleye","year":"2014","journal-title":"Neuroimage"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/4\/684\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:31:05Z","timestamp":1760207465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/18\/4\/684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,23]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,4]]}},"alternative-id":["ijms18040684"],"URL":"https:\/\/doi.org\/10.3390\/ijms18040684","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,23]]}}}